These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 4034868

  • 1. Cholecystokinin potentiates dopamine-mediated behaviors in the nucleus accumbens, a site of CCK-DA co-existence.
    Crawley JN.
    Psychopharmacol Bull; 1985; 21(3):523-7. PubMed ID: 4034868
    [No Abstract] [Full Text] [Related]

  • 2. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH.
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [Abstract] [Full Text] [Related]

  • 3. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function.
    Vaccarino FJ, Rankin J.
    Behav Neurosci; 1989 Aug; 103(4):831-6. PubMed ID: 2765186
    [Abstract] [Full Text] [Related]

  • 4. Electrophysiological effects of cholecystokinin: central dopaminergic systems.
    Wang RY, White FJ.
    Prog Clin Biol Res; 1985 Aug; 192():95-103. PubMed ID: 4080721
    [Abstract] [Full Text] [Related]

  • 5. [Therapeutic value of the coexistence of cholecystokinin and dopamine. Electrophysiological studies in the rat].
    Debonnel G, de Montigny C.
    Encephale; 1989 Aug; 15 Spec No():157-63. PubMed ID: 2743936
    [No Abstract] [Full Text] [Related]

  • 6. GABA-dopamine interaction in substantia nigra and nucleus accumbens--relevance to behavioral stimulation and stereotyped behavior.
    Scheel-Krüger J, Arnt J, Braestrup C, Christensen AV, Cools AR, Magelund G.
    Adv Biochem Psychopharmacol; 1978 Aug; 19():343-6. PubMed ID: 567933
    [No Abstract] [Full Text] [Related]

  • 7. Does cholecystokinin potentiate dopamine action in the nucleus accumbens?
    Wang RY, Hu XT.
    Brain Res; 1986 Aug 20; 380(2):363-7. PubMed ID: 3756487
    [Abstract] [Full Text] [Related]

  • 8. Behavioral interaction between endogenous opioids, CCK-8 and dopaminergic systems in the nucleus accumbens of rats.
    van Ree JM, Igarashi J, Király I.
    NIDA Res Monogr; 1986 Aug 20; 75():323-6. PubMed ID: 2448632
    [Abstract] [Full Text] [Related]

  • 9. Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors.
    Vaccarino FJ.
    Neurosci Biobehav Rev; 1994 Aug 20; 18(2):207-14. PubMed ID: 7914685
    [Abstract] [Full Text] [Related]

  • 10. [Participation of the dopamine of the striatum and the nucleus accumbens in the formation of aggressive and submissive behaviors in mice].
    Kudriavtseva NN, Nikulina EM, Popova NK.
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1988 Aug 20; 38(6):1168-70. PubMed ID: 3245329
    [No Abstract] [Full Text] [Related]

  • 11. On the structural requirements for dopamine-like activity in homogenates of rat nucleus accumbens [proceedings].
    Munday KA, Poat JA, Watling KJ, Woodruff GN.
    Br J Pharmacol; 1977 Sep 20; 61(1):150P-151P. PubMed ID: 912199
    [No Abstract] [Full Text] [Related]

  • 12. Behavioral evidence for the involvement of endogenous opioids in the interaction between cholecystokinin and brain dopamine systems.
    Király I, Van Ree JM.
    Neurosci Lett; 1987 Mar 09; 74(3):343-7. PubMed ID: 3561887
    [Abstract] [Full Text] [Related]

  • 13. The relationship between cholinergic and dopaminergic mechanisms in the nucleus accumbens for the control of locomotor activity [proceedings].
    Costall B, Hui SC, Naylor RJ.
    Br J Pharmacol; 1979 May 09; 66(1):121P-122P. PubMed ID: 454917
    [No Abstract] [Full Text] [Related]

  • 14. Antagonism of cholecystokinin function in the rostral and caudal nucleus accumbens: differential effects on brain stimulation reward.
    Vaccarino FJ, Vaccarino AL.
    Neurosci Lett; 1989 Feb 13; 97(1-2):151-6. PubMed ID: 2918999
    [Abstract] [Full Text] [Related]

  • 15. Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens.
    Crawley JN.
    Brain Res; 1988 Nov 15; 473(2):398-400. PubMed ID: 3233498
    [Abstract] [Full Text] [Related]

  • 16. Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.
    Crawley JN, Hommer DW, Skirboll LR.
    Brain Res; 1985 Jun 03; 335(2):337-41. PubMed ID: 4005562
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Analysis of functional heterogeneity of rat forebrain dopamine-reactive structures].
    Iakimovskiĭ AF.
    Fiziol Zh SSSR Im I M Sechenova; 1981 Sep 03; 67(9):1317-23. PubMed ID: 7297728
    [No Abstract] [Full Text] [Related]

  • 19. Cholecystokinin antagonist lorglumide reverses chronic haloperidol-induced effects on dopamine neurons.
    Jiang LH, Kasser RJ, Wang RY.
    Brain Res; 1988 Nov 08; 473(1):165-8. PubMed ID: 3208120
    [Abstract] [Full Text] [Related]

  • 20. Microiontophoretic studies of the dopaminergic inhibition from the ventral tegmental area to the nucleus accumbens neurons.
    Akaike A, Sasa M, Takaori S.
    J Pharmacol Exp Ther; 1984 Jun 08; 229(3):859-64. PubMed ID: 6726660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.